Merck expanded the label for Welireg by gaining FDA approval to use the drug in combination with Eisai’s Lenvima for a broader group of kidney cancer patients. The update applies to advanced renal cell carcinoma with a clear indication of the therapeutic context for the combined regimen. For oncology development teams, label expansions like this can shift standard-of-care sequencing and broaden eligible treatment lines, especially where combination strategies are becoming increasingly central to disease control. It also reinforces Merck’s strategy of building franchise value by moving from monotherapy into evidence-backed combinations.